Eris Lifesciences Ltd.
NSE: ERIS | BSE: 540596
₹1,340.80
₹-30.10
(-2.20%)
As on 18-May-2026IST
Market cap
₹18,572 Cr
Revenue (TTM)
₹3,078 Cr
P/E Ratio
43
P/B Ratio
5.1
Div. Yield
0.5 %
Quality Score
6/10
Growth Score
7/10
Valuation Score
3/10
Momentum Score
3/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹432 Cr
-
ROE
13.8 %
-
ROCE
13.6 %
-
Industry P/E
33.65
-
EV/EBITDA
18.7
-
Debt to Equity
0.9
-
Book Value
₹261.5
-
EPS
₹32.6
-
Face value
1
-
Shares outstanding
138,567,256
10 Years Aggregate
CFO
₹3,656.87 Cr
EBITDA
₹4,620.48 Cr
Net Profit
₹3,170.97 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
| -10.9 | -7.2 | 0.5 | -8.5 | 28.2 | 13.6 | -- |
|
BSE Healthcare
| 8.9 | 8.8 | 9.5 | 11.4 | 27.0 | 14.4 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
| 13.1 | 51.7 | 40.6 | -14.8 | 28.8 | 16.8 | -31.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
|
1,340.8 | 18,572.2 | 3,078.2 | 469.4 | 26.4 | 14.9 | 43 | 5.1 |
| 3,214.1 | 40,117.5 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 38 | 8.9 | |
| 8,513.5 | 21,254.5 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.8 | 25.6 | |
| 1,986.1 | 15,107.7 | 2,187.2 | 649.7 | 31.5 | 19 | 23.6 | 4.2 | |
| 2,125.3 | 34,116.3 | 4,147.8 | 709.5 | 22.3 | 18.3 | 48.1 | 8.2 | |
| 4,859.3 | 22,234.1 | 2,519.7 | 722.4 | 33.6 | 18.8 | 30.8 | 5.3 | |
| 5,255.0 | 8,734.4 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29.8 | 12.5 | |
| 3,196.9 | 7,383.7 | 1,773.8 | 309.8 | 24.0 | 43.1 | 23.8 | 9.5 | |
| 476.2 | 9,329.3 | 1,432.0 | 149.0 | 19.1 | 7.9 | 62.2 | 3.7 | |
| 1,151.4 | 10,603.1 | 4,858.7 | 574.1 | 14.9 | 19.7 | 19.1 | 3.6 |
Shareholding Pattern
View DetailsNews & Analysis
All News
About Eris Lifesciences
Eris Lifesciences Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in... various therapeutic areas, such as anti"diabetes, anti-infective, blood related, cardiovascular, dermatology, gastrointestinal, gastroenterology, haematinics, hormones, nero/ central nervous system, neuropsychiatry, otologicals, pain/analgesics, respiratory, stomatologicals, cosmetology, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. The company offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India. Read more
-
Incorporated
2007
-
Chairman
Amit Indubhushan Bakshi
-
Managing Director
Amit Indubhushan Bakshi
-
Headquarters
Ahmedabad, Gujarat
-
Website
Looking for more details about Eris Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for Eris Lifesciences
What is the current share price of Eris Lifesciences Ltd Today?
The share price of Eris Lifesciences Ltd is ₹1,340.80 (NSE) and ₹1,340.30 (BSE) as of 18-May-2026 IST. Eris Lifesciences Ltd has given a return of 28.18% in the last 3 years.
What is the current PB & PE ratio of Eris Lifesciences Ltd?
The P/E ratio of Eris Lifesciences Ltd is 43.02 times as on 18-May-2026, a 28 premium to its peers’ median range of 33.65 times.
The P/B ratio of Eris Lifesciences Ltd is 5.13 times as on 18-May-2026, a 12 premium to its peers’ median range of 4.59 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
54.83
|
6.78
|
|
2024
|
29.18
|
4.43
|
|
2023
|
20.36
|
3.55
|
|
2022
|
23.06
|
4.91
|
|
2021
|
23.11
|
5.22
|
What is the 52 Week High and Low of Eris Lifesciences Ltd?
The 52-week high and low of Eris Lifesciences Ltd are Rs 1,910.00 and Rs 1,200.00 as of 19-May-2026.
What is the market cap of Eris Lifesciences Ltd?
Eris Lifesciences Ltd has a market capitalisation of ₹ 18,572 Cr as on 18-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eris Lifesciences Ltd?
Before investing in Eris Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.